<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607188</url>
  </required_header>
  <id_info>
    <org_study_id>ZGALK001</org_study_id>
    <nct_id>NCT03607188</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>A Phase I Tolerance, Safety and Efficacy Study of Alkotinib in Patients With Advanced ALK Postive /ROS1 Positve NSCLC and Previously Treated With Chemotherapy or Crizotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously
      Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind phase 1 trial including 2 sequential parts: single
      ascending dose(SAD) part,multiple ascending dose(MAD) part. SAD and MAD are dose-escalated
      tolerant study designing. The aims of the study as below:

        1. Evaluating the safety and tolerance of ZG0418 in ALK+ NSCLC.

        2. Evaluating the fasting pharmacokinetic parameters of ZG0418 in ALK+ NSCLCJaktinib.

        3. Evaluating the postprandial pharmacokinetic parameters of ZG0418 in ALK+ NSCLC.

        4. Analysis the metabolites of ZG0418
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Day1 to Day25</time_frame>
    <description>Evaluating Dose-Limiting Toxicities (DLTs) from the individuals taking orally dose-escalated Alkatinib</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ZG0418 200mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZG0418 200mg/day,oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZG0418 300mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZG0418 300mg/day,oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZG0418 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZG0418 400mg/day,oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZG0418 500mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZG0418 500mg/day,oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZG0418 600mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZG0418 600mg/day,oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alkotinib</intervention_name>
    <description>Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD</description>
    <arm_group_label>ZG0418 200mg QD</arm_group_label>
    <arm_group_label>ZG0418 300mg QD</arm_group_label>
    <arm_group_label>ZG0418 400mg QD</arm_group_label>
    <arm_group_label>ZG0418 500mg QD</arm_group_label>
    <arm_group_label>ZG0418 600mg QD</arm_group_label>
    <other_name>ZG0418</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.
             (see Appendix A)

          3. Life expectancy of at least 12 weeks.

          4. Ability to swallow and retain oral medication.

          5. Adequate organ system function, defined as follows:

               1. Absolute neutrophil count (ANC) ≥1.5 x 109/L

               2. Platelets ≥75 x 109/L

               3. Hemoglobin ≥9 g/dL (≥90 g/L) Note that transfusions are allowed to meet the
                  required hemoglobin level

               4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

                  ≤2.5 x ULN if no liver involvement or ≤5 x ULN with liver involvement.

               6. Creatinine 1.5 x ULN.

          6. Brain metastases allowed if asymptomatic at study baseline.

          7. Patients must have measurable disease per RECIST v. 1.1.

        Exclusion Criteria:

          1. chemotherapy, radiation therapy, immunotherapy within 4 weeks.

          2. Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             study medications.

          3. uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Eastern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Shi, Master</last_name>
    <phone>13817565470</phone>
    <email>50709035@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Guo, Doctor</last_name>
    <phone>13501678472</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Eastern Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Guo, Doctor</last_name>
      <phone>13501678472</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

